Eli Lilly and Company (NYSE:LLY) Price Target Raised to $879.00

Eli Lilly and Company (NYSE:LLY) had its price objective hoisted by The Goldman Sachs Group from $876.00 to $879.00 in a research note released on Friday,MarketScreener reports. The Goldman Sachs Group currently has a buy rating on the stock.

Several other equities analysts have also recently weighed in on LLY. Deutsche Bank Aktiengesellschaft cut their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a research note on Sunday, August 17th. Finally, Berenberg Bank reaffirmed a “hold” rating and issued a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $948.06.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $833.08 on Friday. The stock has a market capitalization of $788.47 billion, a PE ratio of 54.45, a P/E/G ratio of 1.18 and a beta of 0.47. The business has a 50 day simple moving average of $742.42 and a two-hundred day simple moving average of $765.55. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter last year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Activity

In other Eli Lilly and Company news, Director Gabrielle Sulzberger purchased 117 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director J Erik Fyrwald purchased 1,565 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 4,514 shares of company stock worth $2,894,841 in the last three months. Corporate insiders own 0.14% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently modified their holdings of LLY. Brighton Jones LLC raised its position in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC raised its position in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares in the last quarter. Covestor Ltd raised its position in Eli Lilly and Company by 24.9% during the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after purchasing an additional 85 shares in the last quarter. GAMMA Investing LLC raised its position in Eli Lilly and Company by 25.8% during the 1st quarter. GAMMA Investing LLC now owns 18,000 shares of the company’s stock valued at $14,866,000 after purchasing an additional 3,696 shares in the last quarter. Finally, Warner Financial Inc. raised its position in Eli Lilly and Company by 129.2% during the 1st quarter. Warner Financial Inc. now owns 1,123 shares of the company’s stock valued at $927,000 after purchasing an additional 633 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.